Absci Investor Presentation Deck
CASE STUDY: DE NOVO DESIGN IN SILICO
Laboratory validation straight out of the model;
421 designs confirmed by SPR
We selected trastuzumab, which binds HER2,
as a scaffold to test the HCDR3 predictions
The model is conditioned with HER2 3D
structure and trastuzumab scaffold excluding
HCDR3 designs
E
Antibody
scaffold sequence
Any antibody known to bind to HER2 or any
homolog (>40% sequence identity or part of
the same homologous superfamily)
to HER2 is removed
ABSCI CORPORATION 2023 ALL RIGHTS RESERVED
●
●
●
●
Count
100
80
60
40
20
Trastuzumab
7
-log₁K (M)
440,354 antibody variants designed
Approx. 4,000 estimated binders by ACE
Assay
6
421 confirmed by SPR
71 exhibit <10 nM affinity
3 bind tighter than WT trastuzumab
absci. 14View entire presentation